CAR-T for autoimmune disease
CAR-T cell therapy for lupus, systemic sclerosis and myositis.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 4, 11, 52, 70, 57.
New guidelines and consensus this year
All papers from the last 12 months
509 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- In vivo engineering of CAR immune cells by nonviral nanoparticlesBiomaterials2027 JanPMID 42526199Review
- Targeted delivery of mRNA to immune cells for in vivo cell therapyDrug Deliv2026 Dec 31PMID 42590834Review
- Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in ChinaLancet2026 Dec 20PMID 41240964
- Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticlesMol Ther Nucleic Acids2026 Dec 8PMID 42831101
- 12th Immunotherapy of Cancer Conference (ITOC12): A meeting reportHum Vaccin Immunother2026 DecPMID 42822041
- In vivo immune cell engineering from bench to clinical realityPharm Sci Adv2026 DecPMID 42729695Review
- Chimeric antigen receptor T-cell therapy in systemic lupus erythematosus: From B cell depletion to immune reprogrammingJ Transl Autoimmun2026 DecPMID 42699108Review
- From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseasesAnn Med2026 DecPMID 41657283Review
- Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung diseaseCurr Opin Rheumatol2026 Nov 1PMID 42712119Review
- Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN frameworkCytotherapy2026 NovPMID 42696794Review
More rheumatology trends
All specialties →New lupus treatments
Anifrolumab, belimumab and other targeted drugs in systemic lupus.
Key point: Biologics have been increasingly incorporated into the treatment algorithm at earlier stages of SLE and are first-line treatments for certain manifestations such as lupus nephritis.
Rheumatic immune-related adverse events
Arthritis, myositis and other rheumatic side effects of checkpoint inhibitors.
Ultrasound in rheumatology
Musculoskeletal and vascular ultrasound for diagnosis and monitoring.
Lung disease in systemic sclerosis
Interstitial lung disease in systemic sclerosis.
Giant cell arteritis and PMR
Giant cell arteritis, polymyalgia rheumatica and steroid-sparing treatment.
Key point: In PMR, interleukin-6 receptor blockers should be considered with glucocorticoids for relapsing disease and can be considered for new-onset high-risk patients.
Psoriatic arthritis
Psoriatic arthritis and its targeted treatments.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("CAR-T"[tiab] OR "CAR T"[tiab] OR "chimeric antigen receptor"[tiab]) AND (lupus[tiab] OR autoimmun*[tiab] OR "systemic sclerosis"[tiab] OR myositis[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.